Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: An open, prospective, long-term study

We evaluated the efficacy and safety of lamotrigine in 41 children and youn g adults (age range, 3-25 years; mean, 12 years) with drug-resistant, parti al epilepsies, based on a prospective, add-on study. Patients had severe sy mptomatic/cryptogenic partial epilepsies (mean seizure frequency = 3.6/day) , resistant to one to four major antiepileptic dugs. Mean seizure frequency significantly decreased (P < .001) throughout the period of treatment. A g ood response (>50% seizure reduction) was observed in 15 patients of whom 6 were seizure-free (follow-up: 12-48 months). Higher responder rate was fou nd among cryptogenic epilepsies and epilepsies symptomatic of cerebral malf ormation, whereas patients with posthypoxic-ischemic perinatal. damage were poor responders. Lamotrigine discontinuation was mainly due to lack of eff icacy (46% of patients), whereas only 2 patients developed a transient skin rash and did not drop out. Lamotrigine represents a valuable treatment for severe partial epilepsies of childhood that have proved resistant to previ ous antiepileptic drugs.